High Net Worth Advisory Group’s Theseus Pharmaceuticals, Inc. Common Stock THRX Stock Holding History

High Net Worth Advisory Group’s Portfolio THRX Stock Details THRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-800	Closed	-$5K	–	712
2022 Q3	$5K	Hold	800	–	–	﹤0.01%	593
2022 Q2	$4K	Sell	800 -500	-38%	-$4.13K	﹤0.01%	609
2022 Q1	$15K	Buy	+1,300	New	+$13.9K	0.01%	488

Other funds holding THRX

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

FCMV

Foresite Capital Management V Larkspur, California $271M AUM 309.87% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

High Net Worth Advisory Group's THRX Position: Q4 2022 in Review

High Net Worth Advisory Group sold out of Theseus Pharmaceuticals, Inc. Common Stock (THRX) in Q4 2022, closing a stake of 800 shares — an estimated $5K sold.

High Net Worth Advisory Group first reported a position in THRX in Q1 2022 and held it in 3 quarters. The position peaked at $15K in Q1 2022. 47 funds tracked by Wall St. Rank hold THRX as of Q4 2022.

High Net Worth Advisory Group reported no remaining Theseus Pharmaceuticals, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
High Net Worth Advisory Group sold 800 Theseus Pharmaceuticals, Inc. Common Stock shares in Q4 2022, an estimated $5K.
High Net Worth Advisory Group first reported a position in Theseus Pharmaceuticals, Inc. Common Stock in Q1 2022 and held it in 3 quarters.
High Net Worth Advisory Group's Theseus Pharmaceuticals, Inc. Common Stock position peaked at $15K in Q1 2022.
47 funds tracked by Wall St. Rank held Theseus Pharmaceuticals, Inc. Common Stock as of Q4 2022.

Based on High Net Worth Advisory Group's 13F filing for Q4 2022, filed 14 Feb 2023.